U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505576) titled 'Anti-alpha-actinin Antibodies and Lupus Nephritis Activity' on March 23.
Brief Summary: Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SLE) patients and remains a leading cause of morbidity, with 10-30% progressing to end-stage renal disease within 15 years. The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classifies LN histologically, with proliferative forms (Classes III/IV) carrying the poorest prognosis.
Study Start Date: April 01
Study Type: OBSERVATIONAL
Condition:
Lupus Nephritis
Intervention:
OTHER: renal biopsy
Renal biopsy specimens will be evaluated by light micros...